| Chemical Properties | N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE is White Solid
|
| Originator | Eraldin, I.C.I. ,UK,1970 |
| Uses | Practolol is a selective adrenergic β-receptor blocking drug with antihyperstensive activity. Practolol has been used in the emergency treatment of cardiac arrhythmias. |
| Uses | N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE is a selective adrenergic β-receptor blocking drug with antihyperstensive activity. N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE has been used in the emergency treatment of cardiac arrhythmias.
|
| Definition | ChEBI: N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythm
as. |
| Manufacturing Process | The 1-(4-acetamidophenoxy)-2,3-epoxypropane used as starting material may be obtained as follows. To a solution of 4.5 parts of 4-acetamidophenol and 1.5 parts of sodium hydroxide in 50 parts of water at 15°C, there is added 3.5 parts of epichlorohydrin. The mixture is stirred for 16 hours at ambient temperature, filtered and the solid residue is washed with water. There is thus obtained 1-(4-acetamidophenoxy)-2,3-epoxypropane, MP 110°C.
A mixture of 2 parts of 1-(4-acetamidophenoxy)-2,3-epoxypropane and 10 parts of isopropylamine is stirred at ambient temperature for 16 hours. The resulting solution is evaporated to dryness under reduced pressure and the residue is crystallized from butyl acetate. There is thus obtained 1-(4acetamidophenoxy)-3-isopropylamino-2-propanol, MP 134° to 136°C. |
| Brand name | A 25;Cardiol;Cordialina;Eraldina;Pralon;Teranol. |
| Therapeutic Function | Antiarrhythmic |
| World Health Organization (WHO) | Practolol, a beta-adrenoreceptor antagonist, was introduced in
1970 for the treatment of angina and cardiac dysrhythmias. By 1974 long-term use
had been associated with serious delayed idiosyncratic reactions (oculomucocutaneous
syndrome) and this led to the withdrawal of oral preparations by
the major manufacturer on a worldwide basis. There is no evidence to suggest that
other beta-adrenoreceptor antagonist are associated with this risk. Intravenous
preparations of practolol remain available in many countries for the emergency
treatment of selected cardiac dysrhythmias. |
| Biological Activity | Practolol is a potent and selective β1 adrenergic receptor antagonist. It can be used in the study of cardiac arrhythmias. |
| in vitro | Practolol (10 μM; 30 min) preferentially antagonizes the relaxant effects produced by R0363 in spontaneously contracted tracheal preparations from the guinea-pig.Practolol (10 nM-100 μM) blocks the progesterone production induced by (-)epinephrine in a dose-dependent manner in granulosa cells. |
| in vivo | Practolol (0.5 mg/kg; i.v.) decreases heart rate, left ventricular dP/dt max , myocardial blood flow and cardiac output in intact close-chest dogs.Practolol (0.5 mg/kg; i.v.) decreases normal myocardial blood flow but flow in the ischaemic area remains unchanged after coronary artery ligation. |
